Efavirenz

Bibliography

• MOYLE GJ, GAZZARD BG, COOPER DA, GATELL J: Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs (1998) 55:383-404.
   PubMed Web of Science ®Google Scholar
• D’AQUILA RT: Structural mechanism of HIV drug resistance. Clin. Lab. Med. (1994) 14:393-422.
   PubMed Web of Science ®Google Scholar
• DICENZO R, PETERSON D, GRUTTENDEN K et al.: Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2004) 48:4328-4331.
   PubMed Web of Science ®Google Scholar
• MOYLE G: Protease inhibitor-sparing regimens: new evidence strengthens position. J. AIDS (2003) 33(Suppl. 1):17-25.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al. : Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. (1999) 341:1865-1873.
   PubMed Web of Science ®Google Scholar
• HAAS DW, RIBAUDO HJ, KIM RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 18:2391-2400.
   PubMed Web of Science ®Google Scholar
• DOLIN R, MASUR H, SAAG MS: AIDS Therapy, 2nd edn. Churchill Livingston, New York (2003).
   Google Scholar
• RIDDLER S, HAUBRICH R, DIRIENZO G et al.: A prospective, randomized Phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1. ACTG 5142. 16th International AIDS Conference. Toronto, Canada (13 – 18 August 2006) Abstr. THLB0204.
   Google Scholar
• VAN LETH F, PHANUPKAH P, RUXURUNGTHAM K et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet (2004) 363:1253-1263.
   PubMed Web of Science ®Google Scholar
• MAGGIOLO F, RIPAMONTI D, GREGIS G et al.: Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir. Ther. (2003) 8:83-90.
   Google Scholar
• GALLANT JE, DEJESUS E, ARRIBAS JR et al.: Tenofovir DF, emtricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N. Engl. J. Med. (2006) 354:251-260.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, ARNAIZ JA, PODZAMCZER D et al.: Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. (2003) 349:1036-1046.
   PubMed Web of Science ®Google Scholar
• MAGGIOLO F, RIPAMONTI D, RAVASIO L et al.: Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus Type 1 infection. Clin. Infect. Dis. (2003) 37:41-49.
   PubMed Web of Science ®Google Scholar
• HAUBRICK R, RIDDLER S, DIRIENZO G et al.: Metabolic outcomes of ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA (25 – 28 February 2007) Abstr. 38.
   Google Scholar
• VAN LETH F, PHANUPHAK P, STROES E et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PloS Med. (2004) e19:064-074.
   Google Scholar
• ARRIBAS JR, PULIDO F, MIRO JM et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected, antiretroviral naive patients with fewer than 100 CD4 cells/µL and opportunistic diseases: the EfaVIP study. AIDS (2002) 16:1554-1556.
   PubMed Web of Science ®Google Scholar
• RIBAUDO H, KURITZKES D, LALAMA C, SCHOUTEN J, SCHACKMAN B, GULICK R: Efavirenz-based regimens are potent in treatment-naive patients across a wide range of pre-treatment HIV-1 RNA and CD4 cell counts. 16th International AIDS Conference. Toronto, Canada (13 – 18 August 2006) Abstr. THLB0211.
   Google Scholar
• BACHELER LT, ANTON ED, KUDISH P et al.: Human immunodeficiency type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. (2000) 44:2475-2484.
   PubMed Web of Science ®Google Scholar
• WENSING AMJ, VAN DE VIJER DA, ANGARANO G et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. (2005) 192:958-966.
   PubMed Web of Science ®Google Scholar
• CHERSICH MF, URBAN MF, VENTER FW et al.: Efavirenz use during pregnancy and for women of childbearing potential. AIDS Res. Ther. (2006) 3:11-17.
   PubMedGoogle Scholar
• MANOSUTHI W, KIERTIBURANAKUL S, SUNGKANUPARPH S et al.: Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS (2006) 20:131-132.
   PubMed Web of Science ®Google Scholar
• CLARKE SM, MULCAHY FM, TJIA J et al.: The pharmacokinetics of methadone in HIV-positive patients receiving the nonnucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2001) 51:213-217.
   PubMed Web of Science ®Google Scholar
• MORENO S, HERNANDEZ B, DRONDA F: Antiretroviral therapy in AIDS patients with tuberculosis. AIDS Rev. (2006) 8:115-124.
   PubMed Web of Science ®Google Scholar
• BARTLETT JA, FATH MJ, DEMASI R et al.: An updated systematic review of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS (2006) 20:2051-2064.
   PubMed Web of Science ®Google Scholar
• MAGGIOLO F, RIPAMONTI D, ARICI C et al.: Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials (2002) 3:371-378.
   PubMedGoogle Scholar
• MAGGIOLO F, RAVASIO L, RIPAMONTI D et al.: Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. (2005) 40:158-163.
   PubMed Web of Science ®Google Scholar
• BANGSBERG DR, ACOSTA EP, GUPTA R et al.: Adherence-resistance relationship for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 20:223-231.
   PubMed Web of Science ®Google Scholar
• MAGGIOLO F, AIROLDI M, RAVASIO L et al.: Adherence, virologic outcome and mutation selection: different drugs act differently. 4th European HIV Drug Resistance Workshop. Montecarlo, Monaco (29 – 31 March 2006) Abstr. 56.
   Google Scholar
• MAGGIOLO F, RIPAMONTI D, TORTI C et al.: The effect of HIV-1 resistance mutations after first-line virological failure: possibility to sequence antiretroviral drugs in second-line regimens. Antivir. Ther. (2006) 11:923-929.
   PubMed Web of Science ®Google Scholar